Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $44.2 million.

  • Ani Pharmaceuticals' Net Cash Flow rose 14655.64% to $44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.9 million, marking a year-over-year increase of 34362.11%. This contributed to the annual value of -$75.8 million for FY2024, which is 14512.38% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Net Cash Flow stood at $44.2 million for Q3 2025, which was up 14655.64% from $67.2 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Net Cash Flow high stood at $94.0 million for Q2 2023, and its period low was -$95.0 million during Q3 2024.
  • For the 5-year period, Ani Pharmaceuticals' Net Cash Flow averaged around $13.1 million, with its median value being $7.5 million (2024).
  • In the last 5 years, Ani Pharmaceuticals' Net Cash Flow soared by 94740.93% in 2021 and then plummeted by 156769.42% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Net Cash Flow (Quarter) stood at $85.0 million in 2021, then tumbled by 109.47% to -$8.0 million in 2022, then skyrocketed by 448.36% to $28.0 million in 2023, then crashed by 99.03% to $272000.0 in 2024, then soared by 16163.6% to $44.2 million in 2025.
  • Its Net Cash Flow was $44.2 million in Q3 2025, compared to $67.2 million in Q2 2025 and $5.2 million in Q1 2025.